Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. GILD
stocks logo

GILD

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
7.65B
+1.08%
1.885
-0.79%
7.04B
+5.53%
2.050
+13.26%
7.49B
+5.76%
2.227
+10.8%
Estimates Revision
The market is revising Upward the revenue expectations for Gilead Sciences, Inc. (GILD) for FY2025, with the revenue forecasts being adjusted by 1.6% over the past three months. During the same period, the stock price has changed by 7.79%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.6%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+0.95%
In Past 3 Month
Stock Price
Go Up
up Image
+7.79%
In Past 3 Month
Wall Street analysts forecast GILD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GILD is 133.32 USD with a low forecast of 105.00 USD and a high forecast of 150.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
21 Analyst Rating
Wall Street analysts forecast GILD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GILD is 133.32 USD with a low forecast of 105.00 USD and a high forecast of 150.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Buy
3 Hold
0 Sell
Strong Buy
Current: 127.180
sliders
Low
105.00
Averages
133.32
High
150.00
Current: 127.180
sliders
Low
105.00
Averages
133.32
High
150.00
Scotiabank
NULL -> Outperform
initiated
$140
2025-11-12
Reason
Scotiabank
Price Target
$140
2025-11-12
initiated
NULL -> Outperform
Reason
Scotiabank initiated coverage of Gilead with an Outperform rating and $140 price target.
Truist
Asthika Goonewardene
Buy
maintain
$127 -> $145
2025-11-02
Reason
Truist
Asthika Goonewardene
Price Target
$127 -> $145
2025-11-02
maintain
Buy
Reason
Truist analyst Asthika Goonewardene raised the firm's price target on Gilead to $145 from $127 and keeps a Buy rating on the shares. The company's Q3 results supports the view of a stable base business, but while HIV remains the primary driver with improving PrEP execution, oncology results were mixed and cell therapy continues to face competitive pressure despite broader site access, the analyst tells investors in a research note.
JPMorgan
Chris Schott
Overweight
maintain
$145 -> $150
2025-10-31
Reason
JPMorgan
Chris Schott
Price Target
$145 -> $150
2025-10-31
maintain
Overweight
Reason
JPMorgan analyst Chris Schott raised the firm's price target on Gilead to $150 from $145 and keeps an Overweight rating on the shares post the Q3 report. The firm says the Yeztugo launch is off to an "encouraging start."
RBC Capital
Sector Perform
maintain
$100 -> $105
2025-10-31
Reason
RBC Capital
Price Target
$100 -> $105
2025-10-31
maintain
Sector Perform
Reason
RBC Capital raised the firm's price target on Gilead to $105 from $100 and keeps a Sector Perform rating on the shares after its Q3 results. Yeztugo fell slightly short of expectations, but Q4 guide should reassure launch should not dramatically disappoint, while FY26 should look better, the analyst tells investors in a research note.
Morgan Stanley
Terence Flynn
Overweight
maintain
$143 -> $147
2025-10-31
Reason
Morgan Stanley
Terence Flynn
Price Target
$143 -> $147
2025-10-31
maintain
Overweight
Reason
Morgan Stanley analyst Terence Flynn raised the firm's price target on Gilead to $147 from $143 and keeps an Overweight rating on the shares. Gilead's FY25 guidance for its new Yeztugo HIV PReP launch of $150M implies Q4 sales could come in below the firm's and Visible Alpha consensus forecasts, but the firm believes this is simply a function of building payer access and takes "comfort" from the robust Descovy PReP trends, the analyst tells investors in a post-Q3 note.
Wells Fargo
Overweight
maintain
$140 -> $145
2025-10-31
Reason
Wells Fargo
Price Target
$140 -> $145
2025-10-31
maintain
Overweight
Reason
Wells Fargo raised the firm's price target on Gilead to $145 from $140 and keeps an Overweight rating on the shares. The firm thinks the company's Q3 was strong as Yeztugo real demand was much higher than expectations and HIV strength more than offset cell therapy weakness for guide. Wells continues to see Gilead as its top pick and thinks there is enough to like at 13-times 2026 EPS.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Gilead Sciences Inc (GILD.O) is 14.66, compared to its 5-year average forward P/E of 11.45. For a more detailed relative valuation and DCF analysis to assess Gilead Sciences Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Overvalued
5Y Average PE
11.45
Current PE
14.66
Overvalued PE
14.06
Undervalued PE
8.83

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
8.49
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
9.81
Undervalued EV/EBITDA
7.17

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
5.06
Current PS
124.08
Overvalued PS
17.99
Undervalued PS
-7.87
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 257.52% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 257.52% over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

GILD News & Events

Events Timeline

(ET)
2025-11-18
05:06:55
Gilead Reveals Initial Shipments of Lenacapavir to Eswatini and Zambia
select
2025-11-13 (ET)
2025-11-13
09:55:01
Significant Early Gainers in Liquid Options on November 13th
select
2025-11-13
08:43:15
Gilead reports that ARTISTRY-1 trial has achieved its primary objective.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.0
11-18TipRanks
3 Stocks Indicating 'Buy Now' Opportunities on Technical Charts

  • Market Volatility and Technical Analysis: Amid market fluctuations, technical analysis can help investors identify promising stocks, with TipRanks highlighting NextEra Energy, Danaher, and Gilead Sciences as Strong Buy candidates based on bullish momentum and strong analyst ratings.

  • NextEra Energy Overview: NextEra Energy, a leader in clean energy, is currently in an upward trend with a Strong Buy rating, supported by 12 bullish signals indicating strong upward momentum.

  • Gilead Sciences Insights: Gilead Sciences, known for its antiviral therapies, also holds a Strong Buy consensus, with a positive Rate of Change (ROC) of 5.27, suggesting strong upward momentum and a Buy signal.

  • Danaher Company Profile: Danaher, specializing in life sciences and diagnostics, is rated a Strong Buy based on technical analysis, with a positive ROC of 1.63 indicating strong upward momentum and a Buy signal.

[object Object]
Preview
5.0
11-18Yahoo Finance
Gilead Sciences Sends Initial Shipments of Lenacapavir for HIV Prevention to Eswatini and Zambia
  • Gilead Sciences Announcement: Gilead Sciences has announced the delivery of the first shipments of lenacapavir injection.
  • Product Significance: Lenacapavir is a new treatment option, indicating progress in Gilead's efforts to address health challenges.
[object Object]
Preview
2.0
11-18Barron's
Small Asian Stocks Are Surging in U.S. Markets: Here's Why You Should Avoid Them.
  • Stock Performance: Pheton Holdings closed at a record $30.96 per share, achieving a market capitalization exceeding $200 million.
  • Sales and Profitability: The company reported less than half a million dollars in annual sales and has not yet turned a profit.
  • IPO Success: Since its initial public offering in September 2024, the stock has surged nearly 700%.
  • Lack of News: The significant stock increase occurred despite the absence of any major news or developments related to the company.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Gilead Sciences Inc (GILD) stock price today?

The current price of GILD is 127.18 USD — it has increased 2.49 % in the last trading day.

arrow icon

What is Gilead Sciences Inc (GILD)'s business?

Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. It is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It operates in more than 35 countries worldwide.

arrow icon

What is the price predicton of GILD Stock?

Wall Street analysts forecast GILD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GILD is 133.32 USD with a low forecast of 105.00 USD and a high forecast of 150.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Gilead Sciences Inc (GILD)'s revenue for the last quarter?

Gilead Sciences Inc revenue for the last quarter amounts to 7.77B USD, increased 2.97 % YoY.

arrow icon

What is Gilead Sciences Inc (GILD)'s earnings per share (EPS) for the last quarter?

Gilead Sciences Inc. EPS for the last quarter amounts to 2.43 USD, increased 143.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Gilead Sciences Inc (GILD)'s fundamentals?

The market is revising Upward the revenue expectations for Gilead Sciences, Inc. (GILD) for FY2025, with the revenue forecasts being adjusted by 1.6% over the past three months. During the same period, the stock price has changed by 7.79%.
arrow icon

How many employees does Gilead Sciences Inc (GILD). have?

Gilead Sciences Inc (GILD) has 17600 emplpoyees as of November 19 2025.

arrow icon

What is Gilead Sciences Inc (GILD) market cap?

Today GILD has the market capitalization of 157.79B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto Tracker
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free